[Remote] Key Accounts Manager, Northeast at Corcept Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Candidates should have experience working in target healthcare systems specializing in endocrinology, cardiology, diabetology, orphan disease, or other specialized markets. Proven success engaging with regional- and national-level Key Opinion Leaders (KOLs) to influence institutional practices is required, along with demonstrated ability to establish or influence protocol adoption. Excellent communication skills, strong clinical acumen, and a patient-focused mindset are essential.

Responsibilities

The Key Accounts Manager will develop and execute strategies to drive disease awareness, enhance institutional partnerships, and establish system-wide hypercortisolism screening protocols in targeted healthcare systems. This includes assessing and mapping health system dynamics, building relationships with stakeholders, conducting educational programs, and identifying key individuals to champion system change. The role also involves developing Korlym positioning within healthcare systems, supporting system access through approved educational initiatives, and collaborating with internal teams such as Clinical Specialists, Thought Leader Liaisons, and Medical Science Liaisons.

Skills

Account Management

Relationship Building

Healthcare Systems

Disease Awareness

Strategic Planning

Sales Strategy

Stakeholder Engagement

Cardio-metabolic Diseases

Hypercortisolism

Cushing's Syndrome

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free